Organisation › Details

Karuna Pharmaceuticals Inc.

Karuna is a clinical-stage drug development company focused on targeting muscarinic cholinergic receptors for the treatment of neuropsychiatric disorders including psychosis in schizophrenia, psychosis in Alzheimer’s disease, and pain. Karuna's lead product candidate, KarXT, (Karuna-Xanomeline-Trospium) is being evaluated in a Phase 2 clinical trial in patients with schizophrenia experiencing acute psychosis, with top-line results anticipated at the end of 2019. Karuna, which was founded by PureTech Health (LSE: PRTC), has a worldwide exclusive license for xanomeline and has a patent portfolio more broadly covering selective muscarinic targeting enabled by the KarXT approach. *

 

Period Start 2019-02-24 existent
Period End 2019-03-18 renamed approx
  Group Karuna Therapeutics Inc.
  Today Karuna Therapeutics Inc.
  Successor Karuna Therapeutics Inc.
Products Industry CNS drug
  Industry 2 drug development
     
Region Region Boston, MA
  Country United States (USA)
  Street 33 Arch Street
  City 02110 Boston, MA
    Address record changed: 2019-02-24
     
Basic data Employees n. a.
     
    * Document for �About Section�: Karuna Therapeutics, Inc.. (3/18/19). "Press Release: Karuna Announces $68 Million Series B Financing". Boston, MA.
     
   
Record changed: 2019-03-25

Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 650x112px

More documents for Karuna Therapeutics Inc.


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

[iito] Business Intelligence – The Elephants Are Coming 560x113px




» top